^
    Back
    Association details:
    Biomarker:CD9 expression
    Cancer:Childhood B Acute Lymphoblastic Leukemia
    Drug:KBA1412 (CD9 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

    Published date:
    11/06/2019
    Excerpt:
    Taken together, the majority of precursor B-ALL blasts express CD9 and expression of CD9 is associated with a dismal outcome. Our data demonstrate that CD9 can be successfully targeted by the human CD9 antibody AT1412, suggesting that AT1412 has the potential to be developed as a therapeutic antibody for B-ALL.
    DOI:
    10.1182/blood-2019-127894